The genomic variations in the IGF-1 combined with conventional clinicopathological prognostic markers, along with conventional clinical markers, appeared to be useful for predicting the outcome of metastatic prostate cancer. The gene discussed is IGF1; the disease is metastatic prostate carcinoma.